Compare ACADIA Pharmaceuticals Inc. (ACAD) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs DENTSPLY SIRONA Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while DENTSPLY SIRONA Inc trades at $11.76 (market cap $2.44B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | XRAY | |
|---|---|---|
Market Cap | $4.49B | $2.44B |
Sector | Health | Health |
52-Week High | $28.06 | $16.85 |
52-Week Low | $20.06 | $9.64 |
Enterprise Value | $3.69B | $4.58B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
XRAY trades at $12.19, up 4.64% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $0.27, missing estimates of $0.28, continuing a trend of earnings misses. Revenue declined to $3.68B in 2025 with a net loss of $598M, though gross margin remains healthy at 48.93%. Recent news highlights distribution expansions and AI-enabled product launches, supporting growth initiatives amid ongoing profitability challenges.
The outlook remains mixed: analyst consensus is a 'Hold' with a $12.50 price target, near current levels. Upside potential exists from digital dentistry adoption and cost controls, but risks include persistent net losses, high debt-to-asset ratio of 42.88%, and competitive pressures. Investors should weigh stabilization efforts against margin headwinds and macroeconomic softness in European markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
